COLUMBUS, Ohio — Sensible Medical Innovations Ltd., an Israeli company developing a non-invasive device to monitor patients with congestive heart failure, is opening its first U.S. office, according to the Columbus Dispatch.
In May, Sensible Medical was one of three Israeli heart companies to win a total investment of $1 million from the Global Cardiovascular Innovation Center, which is led by the Cleveland Clinic.
At that time, Sensible Medical had planned to open its Columbus office to work primarily with Dr. William Abraham of Ohio State University by the end of the summer. The Israeli company has been advertising at TechColumbus for an administrator to open and run the office, which it expects to be minimal, at first.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In June, Sensible Medical won a $7 million investment from venture firms SPC Vitalife, in Wayne, Pa., and Tel Aviv, Israel, and Genesis Partners Ltd. of Herzliya Pituach, Israel, according to VCgate.com.
Founded in 2007 as the brainchild of CEO Amir Ronen, Sensible Medical is developing an imaging device that marries medical and information technology to examine internal organs, VCgate said. The device could replace the exploratory surgery now needed to detect congestive heart failure.
The device has been tested in animals and the company is preparing to test it in humans on its way to U.S. Food and Drug Administration approval.
“It’s just a terrific situation from a clinical and from a business standpoint,” Abraham, a professor and director of cardiovascular medicine at Ohio State University, told the Dispatch. “Currently, available tools for monitoring congestive heart failure have failed to keep patients out of the hospital, resulting in a very high cost to patients and to the health care economy.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Sensible has one employee in Ohio, but expects to add more as it tests the device with Ohio State and the Cleveland Clinic, the Dispatch said. Both institutions are part of the Global Cardiovascular Innovation Center, which was started in late 2006 with a $60 million grant from the Ohio Third Frontier project.
